Oncomed Pharmaceuticals Inc (OMED) : Simplex Trading scooped up 21,489 additional shares in Oncomed Pharmaceuticals Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Oct 7, 2016. The investment management firm now holds a total of 24,677 shares of Oncomed Pharmaceuticals Inc which is valued at $279,837.Oncomed Pharmaceuticals Inc makes up approximately 0.04% of Simplex Trading’s portfolio.
Other Hedge Funds, Including , Randolph Co Inc added OMED to its portfolio by purchasing 30,150 company shares during the most recent quarter which is valued at $341,901. Oncomed Pharmaceuticals Inc makes up approx 0.09% of Randolph Co Inc’s portfolio.Bnp Paribas Arbitrage Sa boosted its stake in OMED in the latest quarter, The investment management firm added 881 additional shares and now holds a total of 1,527 shares of Oncomed Pharmaceuticals Inc which is valued at $18,187.
Oncomed Pharmaceuticals Inc opened for trading at $11.31 and hit $11.59 on the upside on Friday, eventually ending the session at $11.34, with a gain of 0.71% or 0.08 points. The heightened volatility saw the trading volume jump to 60,574 shares. Company has a market cap of $348 M.
On the company’s financial health, Oncomed Pharmaceuticals Inc reported $-0.91 EPS for the quarter, missing the analyst consensus estimate by $ -0.11 based on the information available during the earnings call on Aug 9, 2016. Analyst had a consensus of $-0.80. The company had revenue of $6.67 million for the quarter, compared to analysts expectations of $6.05 million. The company’s revenue was up 42.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.72 EPS.
Many Wall Street Analysts have commented on Oncomed Pharmaceuticals Inc. H.C. Wainwright Initiated Oncomed Pharmaceuticals Inc on Sep 22, 2016 to “Buy”, Price Target of the shares are set at $20.
OncoMed Pharmaceuticals Inc. (OncoMed) is a clinical development-stage biopharmaceutical company. The Company focuses on discovering and developing protein therapeutics targeting cancer stem cells (CSCs). The Company’s product candidates target CSCs by blocking self-renewal and driving differentiation of CSCs toward a non-tumorigenic state and also impact bulk tumor cells. Its technology is used to identify isolate and evaluate CSCs; identify and/or validate multiple potential targets and pathways critical to CSC self-renewal and differentiation and develop targeted antibody and other protein-based therapeutics that are designed to modulate these CSC targets and inhibit the growth of CSCs. The Company is also engaged in discovering multiple product candidates that target fundamental biological pathways in immuno-oncology. Its products include Demcizumab AntiDLL4/VEGF bispecific Tarextumab AntiNotch1 Vantictumab Ipafricept Wnt 3rd Biologic Wnt Small Molecules and AntiRSPO.